Physician profile
Katherine D Duncan
NPI 1366762650
$213,585.39
in general payments reported to CMS, 2019-2025
18 companies · $76K in 2025
The $76K reported for 2025 was more than what 94% of Obesity Medicine (Internal Medicine) providers received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.98 · 2021: $403 · 2022: $45K · 2023: $549 · 2024: $92K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $14K · Food and Beverage: $3,089 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,361.19 |
| Travel and Lodging | $14,055.92 |
| Food and Beverage | $3,089.25 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $129,403.49 | 2022-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $83,643.53 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $92.84 | 2025 | |
| Amgen INC. | $91.84 | 2024-2025 | Evenity, Prolia, Prolia |
| Botanix Sb INC | $57.95 | 2025 | Sofdra |
| Leo Pharma INC. | $51.42 | 2023 | Adbry |
| Globus Medical, INC. | $32.57 | 2024 | Simplify Cervical Artificial Disc |
| Corcept Therapeutics | $22.30 | 2025 | Korlym |
| Eisai INC. | $22.09 | 2024 | |
| Medtronic, INC. | $21.87 | 2024 | Micra |
| Sun Pharmaceutical Industries INC. | $20.93 | 2025 | |
| Hologic Sales and Service, LLC | $20.35 | 2024 | Aptima |
| Pfizer INC. | $20.24 | 2024 | |
| Janssen Biotech, INC. | $19.99 | 2022 | |
| Biofrontera INC. | $18.55 | 2025 | Ameluz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15.74 | 2024 | Proclaim |
| Inspire Medical Systems, INC. | $15.71 | 2025 | Inspire |
| Boston Scientific Corporation | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.